278: Merger Mondays, Ozempic panic, & CRISPR'd pigs
We discuss Bristol Myers Squibb’s multibillion-dollar acquisition of Mirati Therapeutics and what it means for a biotech sector still in a slump. We also explain the latest news in the life sciences, including Wall Street’s freakout over GLP-1, CRISPR’ing animals, and the latest in the NASH saga.